Skip to main content Accessibility help
×
Home
  • Print publication year: 2011
  • Online publication date: December 2011

62 - Rehabilitation in multiple sclerosis

from Section IV - Therapy in clinical practice

Summary

The atypical characteristics of primary progressive multiple sclerosis (PPMS) have presented problems in the recruitment to and design of therapeutic trials. The problem areas in the implementation of therapeutic trials are: diagnostic criteria, sample size calculations, and choice of outcome measures. Although there is no definitively proven disease-modifying treatment available for PPMS, several randomized controlled trials have now been specifically designed for this group. The clinical trials in PPMS are based on glatiramer acetate and rituximab. The planned clinical trials in PPMS are based on fingolimod (FTY720) and cladribine. The smaller trials in PPMS are based on Interferon beta-1a, Interferon beta-1b, mitoxantrone and riluzole. A retrospective open-label study of intravenous cyclophosphamide and methylprednisolone in progressive MS included 128 patients with PPMS. PPMS may be the ideal model to investigate disease progression and neuronal protection, and is becoming an important focus for treatment trials in these areas.

References

1. Minaire P. Disease, illness and health: theoretical models of the disablement process. Bull WHO 1992; 70:373–9.
2. International Classification of Functioning, Disability and Health. Geneva: World Health Organization, 2001.
3. Holper L, Coenen M, Weise A, Stucki G, Cieza A, Kesselring J. Characterization of functioning in multiple sclerosis using the ICF. J Neurol 2010; 257(1):103–13.
4. Szabo S, The World Health Organization Quality of Life (WHOQOL) assessment instrument. In Spilker B, Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn Philadelphia: Lippincott-Raven Publishers, 1996.
5. Neuroqol website.
6. Medical Advisory Board of the National Multiple Sclerosis Society, Rehabilitation: Recommendations for Persons with Multiple Sclerosis. National Multiple Sclerosis Society 2005: 10 pp.
7. Chard SE. Community neurorehabilitation: a synthesis of current evidence and future research directions. NeuroRx 2006;3(4):525–34.
8. Hermens H, Huijgen B, Giacomozzi C, et al. Clinical assessment of the HELLODOC tele-rehabilitation service. Annali Dell’Istituto Superiore di Sanita 2008.; 44(2):154–63.
9. Cauraugh JH, Summers JJ. Neural plasticity and bilateral movements: a rehabilitation approach for chronic stroke. Prog Neurobiol 2005; 75(5):309–20.
10. Schaechter JD. Motor rehabilitation and brain plasticity after hemiparetic stroke. Prog Neurobiol 2004; 73(1):61–72.
11. Kwakkel G, Kollen B, Lindeman E. Understanding the pattern of functional recovery after stroke: facts and theories. Restor Neurol Neurosci 2004; 22(3–5):281–99.
12. Filippi M, Rocca MA. Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. Curr Opin Neurol 2003; 16(3):275–82.
13. Beer S, Aschbacher B, Manoglou D, Gamper E, Kool J, Kesselring J. Robot-assisted gait training in multiple sclerosis: a pilot randomized trial. Mult Scler 2008; 14(2):231–6.
14. Lo AC, Triche EW. Improving gait in multiple sclerosis using robot-assisted, body weight supported treadmill training. Neurorehab Neural Repair 2008;22(6):661–71.
15. Carpinella I, Cattaneo D, Abuarqub S, Ferrarin M. Robot-based rehabilitation of the upper limbs in multiple sclerosis: feasibility and preliminary results. J Rehabil Med 2009; 41(12):966–70.
16. Penner IK, Opwis K, Kappos L. Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis. J Neurol 2007; 254 Suppl 2:II53–7.
17. Ottenbacher K. Why rehabilitation research does not work (as well as we think it should), Arch Phys Med Rehabil 1995; 76:123–9.
18. Sharrack B, Hughes R. Clinical scales for multiple sclerosis. J Neuro Sci 1996; 135:1–9.
19. National Multiple Sclerosis Society. M.R.D. Minimal Record Of Disability For Multiple Sclerosis New York: National Multiple Sclerosis Society, 1985.
20. Willoughby E, Paty D. Scales for rating impairment in multiple sclerosis: a critique. Neurology 1988; 38:1793–98.
21. Freeman J, Langdon D, Hobart J, Thompson A. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 1997; 42:236–44.
22. Freeman J, Langdon D, Hobart J, Thompson A. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over in the community? Neurology 1999; 52:50–6.
23. Solari A, Filippini G, Gasco P, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999; 52:57–62.
24. Grasso MG, Pace L, Troisi E, Tonini A, Paolucci S. Prognostic factors in multiple sclerosis rehabilitation. Eur J Phys Rehabil Med 2009; 45(1):47–51.
25. Solari A, Amato M, Bergamaschi R, et al. Accuracy of self-assessment of the minimal record of disability in patients with multiple sclerosis. Acta Neurol Scand 1993; 87:43–6.
26. Sharrack B, Hughes RA. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 1999; 5:223–33.
27. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001; 124:962–73.
28. McGuigan C, Hutchinson M. The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure. J Neurol Neurosurg Psychiatry 2004; 75:266–9.
29. Fischer J, Rudick R, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler 1999; 5:244–50.
30. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373(9665):732–8.
31. Créange A, Serre I, Levasseur M, et al. Réseau SINDEFI-SEP. Walking capacities in multiple sclerosis measured by global positioning system odometer. Mult Scler 2007; 13:220–3.
32. Goldman M, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler 2007; 14:383–90.
33. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982; 284:1607–8.
34. Cattaneo D, Regola A, Meotti M. Validity of six balance disorders scales in persons with multiple sclerosis. Disabil Rehabil 2006; 28(12):789–95.
35. McConvey J, Bennett SE. Reliability of the Dynamic Gait Index in individuals with multiple sclerosis. Arch Phys Med Rehabil 2005 Jan;86(1):130–3.
36. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308:173–80.
37. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003; 60:31–6.
38. Granger C, Cotter A, Hamilton B, Fiedler R, Hens M. Functional assessment scales: a study of persons with multiple sclerosis. Arch Phys Med Rehabil 1990; 71:870–5.
39. Hobart J, Lamping D, Freeman J, et al. Evidence-based measurement: which disability scale for neurologic rehabilitation? Neurology 2001; 57:639–44.
40. Di Fabio R, Soderberg J, Choi T, Hansen C, Schapiro R. Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehabil 1998; 79:141–6.
41. Freeman J, Langdon D, Hobart J, Thompson A. Health-related quality of life in people with multiple sclerosis undergoing inpatient rehabilitation. J Neuro Rehab 1996; 10:185–94.
42. Di Fabio R, Choi T, Soderberg J, Hansen C. Health-related quality of life for patients with multiple sclerosis: influence of rehabilitation. Phys Ther 1997; 77:1704–16.
43. Petajan J, Gappmaier E, White A, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996; 39:432–441.
44. Freeman J, Hobart J, Thompson A. Does adding MS-specific items to a generic measure (the SF-36) improve measurement? Neurology 2001; 57:68–74.
45. Ponitchera-Mulcare J. Exercise and multiple sclerosis. Med Sci Sports Exerc 1993; 25:451–65.
46. McAuley E, Motl RW, Morris KS, et al. Enhancing physical activity adherence and well-being in multiple sclerosis: a randomised controlled trial. Mult Scler 2007; 13(5):652–9.
47. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010; 74;1041–7.
48. Dallmeijer AJ, Beckerman H, de Groot V, van de Port IG, Lankhorst GJ, Dekker J. Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J Rehabil Med 2009; 41(5):322–6.
49. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis (Paralyzed Veterans of America, 1998).
50. Burton JM, Bell CM, Walker SE, O’Connor PW. 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology 2008; 71(22):1833–4.
51. Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007; 13(3):357–68.
52. Schwid SR, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: what is a reliable change? Neurology 2002; 58:1294–6.
53. Cattaneo D, Marazzini F, Crippa A, Cardini R. Do static or dynamic AFOs improve balance? Clin Rehabil 2002; 16(8):894–9.
54. Sheffler LR, Hennessey MT, Knutson JS, Naples GG, Chae J. Functional effect of an ankle foot orthosis on gait in multiple sclerosis: a pilot study. Am J Phys Med Rehabil 2008; 87(1):26–32.
55. Paul L, Rafferty D, Young S, Miller L, Mattison P, McFadyen A. The effect of functional electrical stimulation on the physiological cost of gait in people with multiple sclerosis. Mult Scler 2008; 14(7):954–61.
56. Sutliff MH, Naft JM, Stough DK, Lee JC, Arrigain SS, Bethoux FA. Efficacy and safety of a hip flexion assist orthosis in ambulatory multiple sclerosis patients. Arch Phys Med Rehabil 2008; 89(8):1611–17.
57. Greenspun B, Stineman M, Agri R. Multiple sclerosis and rehabilitation outcome. Arch Phys Med Rehabil 1987; 68:434–437.
58. Khan F. Pallant JF. Brand C. Kilpatrick TJ.. Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008; 79(11):1230–5.
59. Miller DM, Weinstock-Guttman B, Bethoux F, et al. A meta-analysis of Methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 2000; 6:267–73.
60. Bethoux F, Miller D, Kinkel R. Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life. Mult Scler 2000; 7:137–42.
61. Craig J, Young CA, Ennis M, Baker G, Boggild M. A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving steroid treatment. J Neurol Neurosurg Psychiatry 2003; 74:1225–30.
62. Liu C, Playfird ED, Thompson AJ. Does neurorehabilitation have a role in relapsing remitting multiple sclerosis? J Neurol 2003; 250(10):1214–18.
63. Bethoux F, Miller DM, Stough D. Efficacy of outpatient rehabilitation after exacerbations of multiple sclerosis. Arch Phys Med Rehabil 2005; 84:A10.
64. Flavia M, Stampatori C, Zanotti D, Parrinello G, Capra R. Efficacy and specificity of intensive cognitive rehabilitation of attention and executive functions in multiple sclerosis. J Neurol Sci 2010; 288(1–2):101–5.
65. O’Brien AR, Chiaravalloti N, Goverover Y, Deluca J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch Phys Med Rehabil 2008; 89(4):761–9.
66. Rasova K, Feys P, Henze T, et al. Emerging evidence-based physical rehabilitation for multiple sclerosis – towards an inventory of current content across Europe. Health Quality of Life Outcomes 2010; 8:76.